OBJECTIVE: To perform a retrospective economic analysis of The Coronary Angioplasty Amlodipine Restenosis Study (CAPARES), in order to evaluate the pharmacoeconomic profile associated with the use of amlodipine in patients undergoing angioplasty from the perspective of the UK National Health Service. METHODS: A decision analysis was undertaken to track the experiences of patients admitted for angioplasty who were prescribed amlodipine versus those administered placebo. The analysis modeled a four-month time period, which included an initial hospitalization for angioplasty, outpatient follow-up care and any re-admissions for cardiovascular events. The CAPARES trial provided the outcome data for the amlodipine and placebo patients. Outcomes tracked in the analysis included MI, repeat PTCA, CABG, and all-cause mortality. Economic data for inpatient stays, procedures, physician services, laboratory tests and pharmaceuticals were obtained from published data, and a physician panel was used to estimate the quantity of outpatient resource consumption. RESULTS: The total expected cost per patient using and not-using amlodipine was £3,833 and £4,035, respectively, resulting in a net cost savings of £202 over the four-month time period. The cost savings is primarily due to savings in inpatient costs due to the reduction in adverse events requiring repeat revascularization and other events requiring inpatient stays. CONCLUSION: This analysis concludes that in addition to the favourable clinical outcome for angioplasty patients using amlodipine versus placebo demonstrated in the CAPARES trial, a net savings in overall costs may also be realized, resulting in dominance.